Review
Version 1
Preserved in Portico This version is not peer-reviewed
Hematological Neoplasm with Eosinophilia
Version 1
: Received: 1 December 2023 / Approved: 1 December 2023 / Online: 1 December 2023 (16:34:12 CET)
A peer-reviewed article of this Preprint also exists.
Morales-Camacho, R.M.; Caballero-Velázquez, T.; Borrero, J.J.; Bernal, R.; Prats-Martín, C. Hematological Neoplasms with Eosinophilia. Cancers 2024, 16, 337. Morales-Camacho, R.M.; Caballero-Velázquez, T.; Borrero, J.J.; Bernal, R.; Prats-Martín, C. Hematological Neoplasms with Eosinophilia. Cancers 2024, 16, 337.
Abstract
Eosinophils in peripheral blood account for 0.3-5% of leukocytes, which is equivalent to 0.05-0.5 x 109/l. A count equal or above 0.5 x 109/l is considered eosinophilia, while a count equal or above 1.5 x 109/l is defined as hypereosinophilia. In bone marrow, eosinophilia is considered when eosinophils make up more than 6% of the total nuclear cells. In daily clinical practice, the most common causes of reactive eosinophilia are non- hematologic, whether non-neoplastic (allergic diseases, drugs, infections or immunological diseases) or neoplastic (solid tumors). Eosinophilia associated with a haematological malignancy may be reactive or secondary to the production of eosinophilopoietic cytokines, and this is mainly seen in lymphoid neoplasms (Hodgkin lymphoma, mature T-cell neoplasms, lymphoid variant of hypereosinophilic syndrome and B-acute lymphoblastic leukemia/lymphoma). Eosinophilia associated with a haematological malignancy may also be neoplastic or primary, derived from the malignant clone, usually in myeloid neoplasms or with origin in stem cell (myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, acute myeloid leukemia with Core Binding Factor translocations, mastocytosis, myeloproliferative neoplasms, myelodysplastic/myeloproliferative neoplasms and myelodysplastic neoplasms). There are no concrete data in standardized cytological and cytometric procedures that could predict whether eosinophilia is reactive o clonal. The verification is usually indirect, based on the categorization of the accompanying hematologic malignancy. This review focuses on the broad differential diagnosis of haematological malignancies with eosinophilia.
Keywords
Eosinophilia,; hematological neoplasm; myeloid/lymphoid neoplasm with eosinophilia; tyrosine kinase fusion genes; acute leukemia
Subject
Medicine and Pharmacology, Hematology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment